FCRL5, a B-Cell Marker With Novel Diagnostic and Prognostic Value for Multiple Sclerosis
The soluble form of FCRL5 can be measured in the CSF and could serve as a promising biomarker for MS diagnosis and disease activity prediction. In addition, this study highlights that CD19<sup>+</sup>CD11c<sup>+</sup>FCRL5<sup>+</sup> B cells in MS display a distinct transcriptional profile compared with controls.
Authors
- Pietro Maggi (ORCID: https://orcid.org/0000-0003-1697-5585)
- Matthieu Deltombe (ORCID: https://orcid.org/0000-0002-2022-9959)
- Anna Stölting (ORCID: https://orcid.org/0000-0003-0880-0267)
- Vincent Van Pesch (ORCID: https://orcid.org/0000-0003-2885-9004)
Institutions
- Cliniques Universitaires Saint-Luc (BE)
- UCLouvain (BE)
Publication Details
- Journal
- Neurology Neuroimmunology & Neuroinflammation
- Published
- 2025-09-26
- DOI
- https://doi.org/10.1212/nxi.0000000000200485
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00